Phaseline

Targets › ROCK2

ROCK2 (Rho-associated protein kinase 2): drug programs, companies and trials

19 programs from 19 companies in 89 trials: 31 Phase 2, 24 Phase 3, 21 Phase 1, 13 Phase 4; Ophthalmology, Immunology, Oncology; next expected readout Nov 2026.

Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. (UniProt, O75116)

Open in Phaseline: the race on ROCK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiH5 Flu IMP 1
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1, TNFSF4, CD38, IL4RPhase 4RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic …Dec 2026
University of Maryland, BaltimoreNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 4Ocular HypertensionMar 2027
Eye Centers of Southeast TexasNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 4GlaucomaMay 2027
Brett KingNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 4Open Angle Glaucoma (OAG)Jan 2028
Indiana UniversityNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 4GlaucomaJun 2028
East Coast Institute for ResearchNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 4Primary Open Angle Glaucoma or Ocular Hypertension–
Marian Macsai, MDRipasudil hydrochloride hydrate 0.4% ophthalmic solution (Glanatec)
ROCK inhibitor
ROCK1, ROCK2Phase 4Fuchs' Endothelial Dystrophy–
Stanford UniversityRipasudil
Rho-kinase (ROCK) inhibitor
ROCK1, ROCK2Phase 3FuchsNov 2026
Chia Tai Tianqing Pharmaceutical GroupTQ05105 Tablets (Rovadicitinib Tablets)
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr
JAK1, JAK2, ROCK2Phase 3Graft-versus-host Disease; Chronic Graft Versus Host Disease; MyelofibrosisDec 2026
Aurion BiotechCryopreserved AURN001
Corneal endothelial cell therapy with Rho kinase inhibitor
ROCK1, ROCK2Phase 3Corneal EdemaJun 2027
Singapore Eye Research InstituteRipasudil
Rho kinase inhibitor
ROCK1, ROCK2Phase 3Fuchs' Endothelial Dystrophy–
National Institute of Allergy and Infectious Diseases (NIAID)Belumosudil
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Lung TransplantMay 2027
Dana-Farber Cancer InstituteBelumosudil
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Bronchiolitis Obliterans SyndromeJun 2027
Fred Hutchinson Cancer CenterBelumosudil
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Chronic Graft Versus Host DiseaseApr 2028
Woolsey PharmaceuticalsFasudil (WP-0512)
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Amyotrophic Lateral Sclerosis; Prostate Cancer; Prostate CA; Cognitive Decline, Mild …Jan 2029
Memorial Sloan Kettering Cancer CenterBelumosudil
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 2Graft Versus Host DiseaseMay 2029
M.D. Anderson Cancer CenterBelumosudil
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 1Multiple Myeloma; Chronic Graft Versus Host DiseaseAug 2027
University of California, Los AngelesBelumosudil (KD025)
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 1End Stage Kidney DiseaseAug 2028
Massachusetts Eye and Ear InfirmaryNetarsudil
Rho-associated protein kinase inhibitor
ROCK2, ROCK1Phase 1Rhegmatogenous Retinal DetachmentSep 2028

Conditions

Chronic Graft Versus Host Disease (7) Myelofibrosis (5) Dermatitis Atopic (5) Colitis Ulcerative (4) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Asthma (2) Hemophilia (2) Plasma Cell Myeloma (2) Ulcerative Colitis (2) Type 1 Diabetes Mellitus (2) Healthy Volunteers (2)

Modalities

small molecule (16), protein or peptide (2)

Companies

Chia Tai Tianqing Pharmaceutical Group (1) Woolsey Pharmaceuticals (1) Sanofi (1) Massachusetts Eye and Ear Infirmary (1) Dana-Farber Cancer Institute (1) Aurion Biotech (1) University of California, Los Angeles (1) Stanford University (1) University of Maryland, Baltimore (1) Indiana University (1) Singapore Eye Research Institute (1) Marian Macsai, MD (1) Brett King (1) M.D. Anderson Cancer Center (1) East Coast Institute for Research (1) Memorial Sloan Kettering Cancer Center (1) Fred Hutchinson Cancer Center (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Eye Centers of Southeast Texas (1)

Related targets

ROCK1 (18) JAK1 (1) JAK2 (1) TNFSF4 (1) CD38 (1) IL4R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.